To discuss the efficacy and safety of indolbufen in prevention of deep venous thrombosis after hip arthroplasty in elderly patients.

A total of 100 tramatic patients who underwent primary total hip arthroplasty from January 2017 to August 2017 in the department of orthopedics, the third hospital of hebei medical university were collected. 100 patients were randomly divided into two groups: group A (50 cases) was treated with 200 mg of indolebufen, 2/d, and group B (50 cases) was treated with 10 mg of rivaroxaban and 1/d anticoagulant. Anticoagulants were used for at least 35 days in both groups. We observed and compared the incidence of thrombosis, blood loss and coagulation function between the two groups.

There were 13 DVT in 100 cases. In group A, 6 cases (12%) had postoperative venous thrombosis, 4 cases had intramuscular venous thrombosis, and 2 cases had posterior tibial/peroneal venous thrombosis. In group B, 7 cases (14%) had postoperative venous thrombosis, 5 cases had intramuscular venous thrombosis, and 2 cases had posterior tibial/peroneal venous thrombosis. No serious popliteal vein or femoral vein thrombosis occurred in either group. There was no statistically significant difference between group A and group B in the incidence of lower extremity deep vein thrombosis (χ²=0.123, P=0.941). The drainage of patients in both groups was higher on day 1 after surgery than that on day 2 after surgery, and the difference between the drainage on day 1 after surgery and that on day 2 after surgery was statistically significant (group A: t=41.901, P<0.05; Group B: t= 31.185, P<0.05); Patients in both groups had normal preoperative hemoglobin, decreased hemoglobin on the first day after surgery, and almost equal hemoglobin on the seventh day after surgery and the first day after surgery. There was statistically significant difference in hemoglobin between the two groups at different time points (F=17.688, P<0.001). There was no statistically significant difference in hemoglobin between the two groups at different time points (F=0.724, P=0.399). Postoperative PT, APTT and INR of the two groups fluctuated up and down, with only statistical difference in time points (F=10.635, P<0.001; F=5.020, P=0.008; F=9.147, P<0.001). FIB and d-dimmer also fluctuated up and down in the two groups, and there were statistical differences between the groups (F=4.414, P=0.041; F=11.867, P<0.001) and between the time points (F=88.996, P<0.001; F=103.021, P<0.001).

Compared with rivaroxaban, the incidence of deep vein thrombosis in lower extremities after hip arthroplasty was similar in indobufen prevention in elderly patients, with no significant increase in postoperative blood loss.